IHF:NYE-iShares U.S. Healthcare Providers ETF (USD)

ETF | Health |

Last Closing

USD 52.16

Change

-0.35 (-0.67)%

Market Cap

N/A

Volume

0.07M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-20 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.82 (+0.56%)

USD 37.71B
FHLC Fidelity® MSCI Health Care In..

+0.23 (+0.33%)

USD 2.77B
FXH First Trust Health Care AlphaD..

-0.04 (-0.04%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

-0.64 (-0.69%)

USD 0.20B
IDNA iShares Genomics Immunology an..

+0.11 (+0.48%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.03 (+0.09%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-0.98 (-0.95%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.37 (-1.19%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.06 (+0.10%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.06 (-0.26%)

USD 6.89M

ETFs Containing IHF

MSSS Northern Lights Fund Trus.. 10.16 % 0.00 %

-0.09 (-0.31%)

USD 0.11B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.69% 90% A- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.69% 90% A- 83% B
Trailing 12 Months  
Capital Gain -3.41% 15% F 24% F
Dividend Return 0.76% 56% F 10% F
Total Return -2.65% 19% F 20% F
Trailing 5 Years  
Capital Gain 25.14% 52% F 61% D-
Dividend Return 5.00% 58% F 13% F
Total Return 30.14% 52% F 54% F
Average Annual (5 Year Horizon)  
Capital Gain 5.14% 62% D 51% F
Dividend Return 5.78% 62% D 46% F
Total Return 0.64% 63% D 16% F
Risk Return Profile  
Volatility (Standard Deviation) 21.63% 43% F 50% F
Risk Adjusted Return 26.73% 57% F 41% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.